IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	e patent application of:				Defende Provide			
Alex	ander	L. K	libanov et al.)	Before the Examiner Marianne Dibrino			
Appl	licatio	n No	. 10/511,383)	Group Art Unit			
Filed May 18, 2005					1644			
			LE COMPOSITIONS, AND OR PREPARING AND USING SAME)	Confirmation No. 5031			
			INFORMATION DISCLOSUI	RE S	STATEMENT			
Com PO E	3ox 14	oner:	for Patents 22313-1450					
1.	List	List of All Patents. Publications, U.S. Applications, or Other Information						
	Pursuant to the provisions of 37 CFR 1.56, 1.97, and 1.98, Applicant requests consideration of the references listed on the attached PTO/SB/08 form(s) (commonly referred to as a PTO-1449 form) and/or the additional information identified below.							
2	Enclosed Legible Copies							
	2a.	A le PTO	egible copy of each foreign patent docur D/SB/08 form is enclosed,	nen	t and publication listed on the			
		i.	except, a copy is <u>not</u> provided for each submitted to the Patent Office in prior, filed filed laims priority under 35 U.S.C. §120.	U.S	erence previously cited by or Patent Application Serial No. m which the present application			
		ii.	except, a copy is <u>not</u> provided for each reference identified below:	cun	nulative reference and enclosed			
	2b.	A c	opy of the specification and drawings folication.	or ea	ch cited unpublished U.S.			

Information Disclosure Statement Serial No. 10/511,383 Attorney Docket: 22078-2 Page 1 of 4 #579754

	2c.	A copy of a Search Report or Written Opinion from a foreign patent office is also enclosed.						
	2d.	Consideration of the enclosed additional and/or below discussed information is requested.						
3.	Con	cise Explanation of Relevance for Non-English Language Information						
For e	or each non-English language reference listed on the attached SB/08 form(s), reference is made or							
	3a.	an English language translation submitted herewith,						
	3b.	foreign patent office Search Report (in the English language) submitted herewith,						
	3c.	an English language translation of a foreign patent office Search Report submitted herewith,						
	3d.	the concise explanation contained in the present application at page(s),						
	3e.	the concise explanation set forth in the attached English language abstract,						
	3f.	a copy of a related patent publication (in the English language) cited herewith,						
		Foreign Patent Document Corresponding English Language Patent Document Patent Document						
	3g.	the following concise explanation:						
4.	Time	e for Filing						
	4a.	This Information Disclosure Statement is submitted:						
		i. for U.S. national applications or national stage PCT applications (not including CPAs and RCEs), within 3 months of filing or entry into national stage; \underline{or}						
		ii. for U.S. national applications, national stage PCT applications, CPAs or RCEs, before the first Office Action on the merits,						
	and t	thus no certification and/or fee is required.						
\boxtimes	4b.	This information Disclosure Statement is submitted after three months from the						

filing date and after the first Office Action on the merits, but prior to the mailing date

of a final Office Action or Notice of Allowance, and thus:

Information Disclosure Statement Serial No. 10/511,383 Attorney Docket: 22078-2

Page 2 of 4 #579754

		i.	the statement specified in 37 CFR §1.97(e) is provided below, \underline{or}		
	\boxtimes	ii.	a fee of $$180.00$ (set forth in 37 CFR $$1.17(p)$) is enclosed.		
	4c.	This Information Disclosure Statement is submitted after the mailing date of a Office Action or Notice of Allowance and prior to payment of the issue fee, a thus:			
		i.	the statement specified in 37 CFR $\S1.97(e)$ is provided below, <u>and</u> a fee of \S (set forth in 37 CFR $\S1.17(p)$) is enclosed, <u>or</u>		
		ii.	a Request for Continued Examination (RCE) and fee of 37 CFR $1.17(e)$ has been filed.		
	4d.	This Information Disclosure Statement is submitted after payment of the issue fee, and thus:			
		i.	a Petition to Withdraw from Issue pursuant to 37 CFR $1.313(e)(2)$ has been filed, and		
		ii.	a Request for Continued Examination (RCE) and fee of 37 CFR $\$1.17(e)$ has been filed.		
5.	Cert	ification- Statement Under 37 CFR 1.97(e)			
	5a.	It is hereby certified that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.			
	5b.	A copy of a dated communication from a foreign patent office which clearly shows the statement is being submitted within three (3) months of the date on the communication is enclosed.			
	5c.	It is hereby certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filling of this Information Disclosure Statement.			

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined

in §1.56(b). It is believed that no additional fees are required. Should any other fee be required, however, please charge such fee to Deposit Account No. 23-3030, but not to include any payment of issue fees.

Respectfully submitted,

Kenneth A. Gandy, Reg. No. 33,386 Woodard, Emhardt, Morianty, McNett & Henry LLP 111 Monument Circle, Suite 3700 Indianapolis, Indiana 46204-5137

(317) 634-3456